Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes

Leukemia

Volumn 10, Issue 4, 1996, Pages 693-699

  Greco, G ^a   Fruci, D ^a   Accapezzato, D ^b   Barnaba, V ^b   Nisini, R ^c   Alimena, G ^b   Montefusco, E ^b   Vigneti, E ^a   Butler, R ^a   Tanigaki, N ^a,d   Tosi, R ^a,e  

^a CNR   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c DASRS   (Italy)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e Instituto di Biologia Cellulare   (Italy)

Author keywords

CML; CTL; HLA class I; Junction peptides

Indexed keywords

BCR ABL PROTEIN; CD8 ANTIGEN; HLA A3 ANTIGEN; HLA ANTIGEN CLASS 1; PEPTIDE FRAGMENT;

AMINO ACID SUBSTITUTION; ANTIGEN BINDING; ARTICLE; B LYMPHOBLAST; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN BINDING; T LYMPHOCYTE; AMINO ACID SEQUENCE; BINDING SITE; CHEMISTRY; CHROMOSOME 22; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; DRUG EFFECT; GENE TRANSLOCATION; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PROTEIN FOLDING; SYNTHESIS;

AMINO ACID SEQUENCE; BINDING SITES; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; CYTOTOXICITY, IMMUNOLOGIC; FUSION PROTEINS, BCR-ABL; HLA-A3 ANTIGEN; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PHILADELPHIA CHROMOSOME; PROTEIN FOLDING; T-LYMPHOCYTES, CYTOTOXIC; TRANSLOCATION, GENETIC;

EID: 0029665066     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Van Etten RA, Jackson P, Baltimore D. The mouse type IV c-abl gene product is a nuclear protein and activation of transforming ability is associated with cytoplasmic localization. Cell 1989; 58: 669-678.
2. Falk K, Rotzschkle O, Stevanovic S, Jung G, Rammensee H-G Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351: 290-296.
3. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley D Identification of self-peptides bound to purified HLA-B27. Nature 1991; 353: 326-329.
4. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E, Engelhard VH. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992; 255: 1261-1263.
5. Rotzschke O, Falk K, Stevanovic S, Jung G, Rammensee H-G. Peptide motifs of closely related HLA class I molecules encompass substantial differences. Eur J Immunol 1992; 22: 2453-2456.
6. Faber JM, van Luxemberg S, Willemze R, Falkenburg I. Generation of leukemia-reactive cytotoxic T-lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 1992, 176: 1283-1289.
7. Ramensee HG, Friede T, Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995; 41: 178-228.
8. Rovero P, Riganelli D, Fruci D, Vigano S, Pegoraro S, Revoltella R, Greco G, Butler R, Clementi S, Tanigaki N. The importance of secondary anchor residue motifs of HLA class I proteins: a chemometric approach. Mol Immunol 1994; 31: 549-554.
9. Ruppert J, Sidney J, Celis E, Kubo R, Grey H, Sette A. Prominent role of secondary anchor residues in peptide binding in HLA-A2.1 molecules. Cell 1993; 74: 929-937.
10. Madden DR, Garboczi DN, Wiley DC. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 1993; 75: 693-708.
11. Cullis JO, Barrett AJ, Goldman JM, Lechler RJ. Binding of bcr/abl junctional peptides to MHC class I molecules: studies in antigen processing defective cell lines. Leukemia 1994; 8: 165-170.
12. Tanigaki N, Fruci D, Chersi A, Butler RH. Unfolded HLA class I alpha chains and their use in an assay of HLA class I-peptide binding. Hum Immunol 1993; 36: 119-127
13. Wiegant J, Ried T, Nederlof PM, Van der Ploegh M, Tanke HJ, Raap AK. In situ hybridisation with fluoresceinated DNA. Nucleic Acid Res 1991; 19: 3237-3241.
14. LoCoco F, Mandelli F, Diverio D, Alimena G, De Fabritilis P, Meloni G, Cedrone M, Frontani M, Guerrazio A, Saglio G. Therapy induced Ph′ suppression in chronic myeloid leukemia. Molecular cytogenetics studies in patients treated with alpha 2b interferon, high-dose chemotherapy and autologous stem cell infusion. Bone Marrow Transplant 1990; 6: 253-258.
15. Gagliardi MC, De Petrillo G, Salemi S, Boffa L, Longobardi MG, Dellabona P, Casorati G, Tanigaki N, Harris R, Lanzavecchia A, Barnaba V. Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro. Int Immunol 1995; 7: 1741-1752.
16. Tanigaki N, Fruci D, Groome N, Butler R, Londei M, Tosi R. Exploring myelin basic protein for HLA class 1 binding sequences. Eur J Immunol 1994; 24: 2196-2202.
17. Fruci D, Greco G, Vigneti E, Tanigaki N, Butler R, Tosi R. The peptide binding specificity of HLA-B27 subtype (B*2705) analysed by the use of polyalanine model peptides. Hum Immunol 1994; 41: 34-38.
18. Gao X, Jakobsen IB, Serjeantson SW. Characterization of the HLA-A polymorphism by locus-specific polymerase chain reaction amplification and oligonucleotide hybridization. Hum Immunol 1994; 41: 267-279.
19. van Endert PM, Riganelli D, Greco G, Fleischhauer K, Sidney J, Sette A, Bach JF. The peptide binding motif for the human transporter associated with antigen processing (TAP). J Exp Med 1995; 182: 1883-1895.
20. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJM, Oseroff C, Yuan L, Ruppert J, Sidney J, del Guercio MF, Southwood S, Kubo RT, Chesnut RW, Grey HM, Chisari FV. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994; 153: 5586-5592.
21. Chen W, Peace D, Rovira D, You S, Cheever MA. T cell immunity to the joining region of p210 bcr-abl protein. Proc Natl Acad Sci USA 1992; 89: 1468-1472.
22. Kast WM, Brandt RMP, Sidney J, Drijfhout J-W, Kubo RT, Grey HM, Melief CJM, Sette A. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994; 152: 3904-3924.
23. Christinck ER, Luscher MA, Barber BH, Williams DB. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 1991; 352: 67-69.
24. Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler LM. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 1989; 143: 2714-2722.
25. Di Brino M, parker KC, Shiloach J, Knierman M, Lukszo J, Turner RV, Biddison WE, Coligan JE. Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides. Proc Natl Acad Sci USA 1993; 90: 1508-1512.
26. Van Denderen J, ten Hacken P, Berendes P, Zegers N, Boersma W, Grosveld G, van Ewijk W. Antibody recognition of the tumor-specific b3-a2 junction of bcr-abl chimeric proteins in Philadelphia-chromosome-positive leukemias. Leukemia 1992; 6: 1107-1112.
27. Richiardi PM, Tosi R, Martinelli G, Saglio G, Conte R, Barbanti M, Dall'Omo A, Farabegoli P, Favoino B, Gambelunghe C, Gandini AR, Marceno R, Misefari V, Mulargia M, Pratico L, Zaccaria A. The HLA class I-CML association revisited taking into acount the two forms of gene fusion in the Philadelphia chromosome. A multicenter study. Leukemia 1994; 8: 2134-2137.
28. Dorak M, Chalmers EA, Gaffney D, Wilson DWL, Galbrait I, Henderson N, Worwood M, Mills KI, Burnett AK. Human major histocompatibility complex contains several leukemia susceptibility genes. Leuk Lymphoma 1994; 12: 211-222.